Healthcare Stakeholder Perspectives on a Value Assessment Approach for Duchenne Muscular Dystrophy Therapies
-
Published:2024-08
Issue:
Volume:Volume 17
Page:4199-4212
-
ISSN:1178-2390
-
Container-title:Journal of Multidisciplinary Healthcare
-
language:en
-
Short-container-title:JMDH
Author:
Fischer Ryan,
Furlong PatORCID,
Kennedy Annie,
Maynard Kelly,
Penrod Marissa,
Miller Debra,
Laverty Chamindra,
Lowes Linda,
Kuntz Nancy,
Shieh Perry,
Kondejewski Jane,
Neumann Peter,
Shafrin JasonORCID,
Willke Richard
Publisher
Informa UK Limited
Reference41 articles.
1. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management
2. Centers for Disease Control and Prevention- MMWR Weekly. Available from: https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5840a1.htm#:~:text=Birth%20prevalence%20of%20DMD%20has,)%20male%20births%20(5). Accessed June 22, 2023.
3. Prognostic indicators of disease progression in Duchenne muscular dystrophy: A literature review and evidence synthesis
4. Real-world outcomes of long-term prednisone and deflazacort use in patients with Duchenne muscular dystrophy: experience at a single, large care center
5. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management